New Data Shows JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-to-Severe Plaque Psoriasis Through One Year

SAN DIEGO (March 9, 2024)– Johnson& Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials